International Federation For The Surgery Of Obesity Research Articles

Position statement and guidelines about Endoscopic Sleeve Gastroplasty (ESG) also known as "Endo-sleeve".

IS ESG EFFECTIVE IN THE TREATMENT OF OBESITY AND ASSOCIATEDCOMORBIDITIES?: Endoscopic Sleeve Gastroplasty (ESG) is more effective than lifestyle modifications alone for weight loss and improving obesity-related comorbidities. While it has less effect on weight loss compared to Laparoscopic Sleeve Gastrectomy (LSG) in the short to medium term, it offers similar comorbidities resolution to LSG. IS ESG A SAFE PROCEDURE, AND WHAT ARE ITS RISKS?: The safety profile of ESG is consistently supported in the literature. Surgical complications after ESG, ranging from 1.5 to 2.3%, such as bleeding, perforation, fistula, or upper bowel obstruction, are rare and typically managed endoscopically. The incidence of new-onset gastro-esophageal reflux disease (GERD) is deemed negligible and occurs less frequently after ESG compared to SG. WHAT ARE THE INDICATIONS AND MANAGEMENT METHODS?: Multidisciplinary care for patients undergoing ESG should be provided in an accredited center authorized to perform bariatric and metabolic surgery, with validation through a multidisciplinary consultation meeting (RCP). Perioperative management should be personalized and ideally modeled after the protocols already in place for bariatric and metabolic surgery to ensure satisfactory and lasting weight and metabolic outcomes. Adherence to follow-up visits is a significant predictor of successful weight loss outcomes after ESG. Additionally, all endoscopic surgical procedures should be documented in a registry affiliated with a recognized scientific society, as is standard for other bariatric surgical procedures. WHICH HEALTHCARE PROFESSIONALS CAN PERFORM ESG?: ESG must be performed by a practitioner trained in endoscopy and obesity management, capable of ensuring thorough preoperative care and comprehensive postoperative follow-up, supported by an experienced multidisciplinary team. In France, Notice No. 2021.0040/AC/SEAP of June 10, 2021, issued by the Haute Autorité de santé (HAS) college, specifies that "the technology of ESG via the trans-oral approach, involving wide plication of the greater gastric curvature […] with an endoscopic suture placement device, enables a gastroenterologist or a visceral and digestive surgeon to perform gastric plication through digestive endoscopy by placing sutures in the stomach". Ideally, this should take place in an accredited center authorized to perform bariatric and metabolic surgery, such as those approved by the Agence régionale de santé (ARS), in accordance with Article R6123-212 of December 2022 of the French Public Health Code. WHAT ARE THE RECOMMENDATIONS AND VIEWS OF OTHER INTERNATIONAL SCIENTIFICSOCIETIES?: ESG is an integral part of the therapeutic arsenal available to bariatric and metabolic surgeons, offering an effective and valuable treatment option for obesity in specific patient populations. The International Federation for the Surgery of Obesity (IFSO) Bariatric Endoscopy Committee, following a comprehensive systematic review and meta-analysis, endorsed ESG as an effective and valuable treatment for obesity. ESG is particularly beneficial for patients with class I and II obesity, as well as for those with class III obesity who are not suitable candidates for metabolic bariatric surgery. Additionally, it can be proposed as an addition to lifestyle interventions in adolescent patients with class II obesity. The SOFFCOMM endorses endoscopic sleeve gastroplasty (ESG) as an effective and valuable treatment for obesity and highlights the importance of appropriate patient selection, coupled with rigorous evaluation of long-term outcomes, to refine its indications further.

Long-Term Safety and Efficacy of Bariatric Surgery in Septuagenarians.

Metabolic and bariatric surgery (MBS) has been shown to be safe and effective in the elderly population. Unfortunately, utilization of MBS in patients aged 70 years or older remains low, as MBS was just recently endorsed by the American Society for Metabolic and Bariatric Surgery (ASMBS) and the International Federation for the Surgery of Obesity (IFSO) for septuagenarians. We performed a single-center retrospective cohort study of 103 patients aged ≥ 70 years who underwent sleeve gastrectomy (SG) or Roux-en-Y gastric bypass (RYGB) from January 2008 until March 2023. The data analyzed included patient demographics, post-operative complications, resolution of obesity-related comorbidities, and weight loss. A total of 103 patients (71% female; age 72.1 ± 2.5 years; BMI 43.7 ± 6.8 kg/m2) were included. Sixty-two patients (60.2%) underwent RYGB while the remaining 41 underwent SG (39.8%), with a mean follow-up of 4.7 ± 3.7 years. There was no MBS-related mortality. All-cause mortality rates were 7.3% for the SG group after a mean period of 4.5 ± 3.9 years compared to 8.1% for the RYGB cohort after 7.7 ± 3.5 years (p = 0.601). RYGB was reported to have a higher rate of early and late complications when compared to LSG (p = 0.083 and p = 0.274). T2DM (p = 0.011) and OSA (p = 0.019) resolved significantly after RYGB. Our study demonstrates that bariatric surgery is safe and effective in patients aged 70 years and older. Bariatric surgery should not be denied to this group of patients based on chronological age alone. Further studies are required to support these findings.

The Effect of Longitudinal Gastric Resection in Morbid Obesity Surgery on the Course of Insulin-Dependent Diabetes and Gastroesophageal Reflux Disease

Longitudinal resection of the stomach is a relatively new type of gastroplasty within the framework of bariatric surgery, which is gaining popularity worldwide today not only as a method of getting rid of excess subcutaneous fat, but also from a range of serious chronic diseases together. The potential of longitudinal gastric resection turned out to be promising, and if the first performed longitudinal gastric resection in 1988 was only a restrictive stage of biliopancreotic bypass surgery, then since the 2000s, laparoscopic longitudinal resection has been started as a deliberately first stage in patients with morbid obesity with high operational risk. To date, longitudinal gastric resection has become increasingly used in particularly difficult cases in the form of independent surgical intervention, for example, in the elderly, teenagers, people with cirrhosis of the liver and other severe pathologies. At the initial stages of the formation of this type of treatment, different surgeons did not have a common opinion on many issues related to the technique of this operation. And therefore, to date, the data on the longitudinal resection of the stomach of many years ago are contradictory. They do not create a holistic view of the effectiveness of surgical intervention, especially in the long term. According to IFSO (The International Federation for the Surgery of Obesity and Metabolic Disorders) data, in 2012, longitudinal gastric resection accounted for 27.8% of all bariatric operations, which even then overtook the gastric banding operation in terms of the number of operations. Over the past 20 years, a little more than 250 thousand such operations have been performed worldwide, and the frequency of performing longitudinal gastric resection increases every year.
 The purpose of this article is to reveal the statistics of the effectiveness of longitudinal gastric resection.

Sleeve-forming gastrectomy is the right terminology.

Gastric sleeve is the final result when a vertical or sleeve-forming gastrectomy is performed. There is controversy about the nomination of the procedure to make a lesser curvature gastric sleeve (LCS) since the term sleeve gastrectomy, used commonly, is grammatically a misnomer. Lexicon incorrectness should not be accepted scientifically for any nomination. The Spanish Royal Academy of Medicine and seven leaders of the International Federation for the Surgery of Obesity (IFSO) were consulted. Four past IFSO presidents, four chief editors of the Obesity Surgery journal and two presidents of national associations all agree that the sleeve gastrectomy term is a misnomer and sleeve-forming gastrectomy is proposed as the correct term.

Interview: Metabolic/bariatric surgery

Attended Columbia College (Valedictorian, 1954) and the College of Physicians and Surgeons of Columbia University. He studied under Drs Wangensteen and Varco at the University of Minnesota (USA). He is Professor of Surgery and Biomedical Engineering at the University of Minnesota, and was the first Owen H and Sarah Davidson Wangensteen Chair in Experimental Surgery at the University of Minnesota. Dr Buchwald served as President of the International Federation for the Surgery of Obesity (IFSO), American Society for Metabolic/Bariatric Surgery (ASMBS), Central Surgical Association, International Study Group for Implantable Insulin Delivery Devices and the Owen H Wangensteen Society. He was principal investigator of the Program on the Surgical Control of the Hyperlipidemias (POSCH), the first randomized clinical trial to demonstrate, in 1990, that cholesterol lowering via the partial ileal bypass resulted in reductions in myocardial infarctions, angina pectoris and peripheral vascular disease; arteriographic...

The Evolution of IFSO

Last September, at the General Council Meeting of the International Federation for the Surgery of Obesity (IFSO) in Porto, Portugal, a new name was proposed for our Federation, in order to be in accordance with the new perspectives in our discipline. The name International Federation for the Surgery of Obesity and Metabolic Disorders was approved. Also, it was accepted to maintain the initials IFSO. I remember that historic day in 1995 when IFSO was founded in Stockholm, Sweden, and 12 years later, we are thrilled with the extraordinary development of our Federation, and the increasing participation of colleagues from the many countries and many national bariatric societies. Our traditional annual meeting – The World Congress – is a “must” for every bariatric surgeon and allied health professional to attend. Our official journal, Obesity Surgery, is considered the best in its field, thanks to the unique devotion and dedication of Mervyn Deitel, who, almost alone, prepared, edited, and published the Journal since its formation. Now, we have signed a contract with Springer Science & Business Media to continue the high quality of the Journal. We are happy with these accomplishments, but we recognize that our task is far from over; new achievements pose new questions. I want to mention only three. In spite of the beneficial results of some bariatric techniques on nonobese individuals with type 2 diabetes, we do not have a complete explanation, and we still do not know if these results will last for the years to come. Besides, the basic question remains: what is obesity? We have a major challenge and should work along with endocrinologists, neuroscientists, geneticists, and other specialists to get to the core of the problem, truly understand what obesity is, and finally cure it. Second, although we are pleased with the results of weight loss and amelioration of comorbidities, we must also devote more study to quality of life, which should be our most important concern. Third, although every IFSO member has a code of bioethics in his/her daily practice, it is proper to draw up a Code of Ethics in our discipline for patient selection, indications, thorough information for the patient, techniques, follow-up, and gathering and publishing results. With its new name, IFSO enters a new era. As a Federation, we should promote the best bariatric surgery internationally, through the accreditation of centers of excellence, as was presented by our past president, Professor John Melissas. IFSO should promote optimal surgical techniques and multidisciplinary groups. I am grateful to our masters and teachers, pioneers who opened this field more than 50 years ago. I am also excited with our ambitious goals for our future. As President of IFSO, I respectfully ask for your help in your clinics, hospitals, and bariatric societies, and also in our IFSO website (www.ifso.com), where your comments and proposals are important. Your participation will make IFSO what we all dreamed of that day in Stockholm in 1995. OBES SURG (2008) 18:767 DOI 10.1007/s11695-007-9370-1

The Future of the International Federation for the Surgery of Obesity (IFSO)

The Future of the International Federation for the Surgery of Obesity (IFSO)

Bariatric Surgery Worldwide 2003

There is a world epidemic of overweight, obesity, and morbid obesity, encompassing 1.7 billion people. Bariatric surgery today is the only effective therapy for morbid obesity. E-mail requests for information were sent to the presidents of the national societies of the 31 International Federation for the Surgery of Obesity (IFSO) nations, or national groupings, plus Sweden. Responses were tabulated; calculation of relative prevalence of specific procedures was done by weighted averages. Responders were 26 of 32 (81%) for the general questions and 24 of 32 (75%) for the question on specific operative percentages. In the year 2002-2003, 146,301 bariatric surgery operations were performed by 2,839 bariatric surgeons; 103,000 of these operations were performed in USA/Canada by 850 surgeons. The earliest start date for bariatric surgery was 1953 in the USA; IFSO was founded in 1995. In the year 2002-2003, 37.15% of operations were open; 62.85% laparoscopic. The 6 most popular procedures by weighted averages were: laparoscopic gastric bypass, 25.67%; laparoscopic adjustable gastric banding, 24.14%; open gastric bypass, 23.07%; laparoscopic long-limb gastric bypass, 8.9%; open long-limb gastric bypass, 7.45%; and open vertical banded gastroplasty, 4.25%. Pooling open and laparoscopic procedures, relative percentages were: gastric bypass, 65.11%; gastric banding, 24.41%; vertical banded gastroplasty, 5.43%; and biliopancreatic diversion/duodenal switch, 4.85%. Categorizing into restrictive/malabsorptive, purely restrictive, and primarily malabsorptive, the relative distribution of procedures was 65.11%, 29.84%, and 4.85%, respectively. The number of countries performing gastric banding was 23 (95%), gastric bypass 21 (88%), vertical banded gastroplasty 19 (79%), and biliopancreatic diversion/duodenal switch 16 (67%). Purely restrictive procedures were performed in 24 (100%) of the countries, restrictive/malabsorptive in 21 (88%), and primarily malabsorptive in 18 (75%). Bariatric surgery is expanding exponentially to meet the global epidemic of morbid obesity. Operative procedures in bariatric surgery are in flux and specific geographic trends and shifts are evident. Yet, of the patients qualifying for surgery, only about 1% are receiving this therapy--the only effective treatment currently available.

9th World Congress of the International Federation For the Surgery of Obesity (IFSO)

9th World Congress of the International Federation For the Surgery of Obesity (IFSO)

8th World Congress of the International Federation for the Surgery of Obesity (IFSO)<BR></BR> 5th International Symposium on Laparoscopic Obesity Surgery (ISLOS)<BR></BR> 17th International Symposium on Obesity Surgery

8th World Congress of the International Federation for the Surgery of Obesity (IFSO)<BR></BR> 5th International Symposium on Laparoscopic Obesity Surgery (ISLOS)<BR></BR> 17th International Symposium on Obesity Surgery

Executive Council and Representatives of the International Federation for the Surgery of Obesity (IFSO), 2002

Executive Council and Representatives of the International Federation for the Surgery of Obesity (IFSO), 2002

6th World Congress of the International Federation for the Surgery of Obesity (IFSO), 3rd International Symposium on Laparoscopic Obesity Surgery (ISLOS) International and Symposium on Obesity Surgery: September 5-8th, 2001, Chania, Crete, Greece

6th World Congress of the International Federation for the Surgery of Obesity (IFSO), 3rd International Symposium on Laparoscopic Obesity Surgery (ISLOS) International and Symposium on Obesity Surgery: September 5-8th, 2001, Chania, Crete, Greece

6th World Congress of the International Federation for the Surgery of Obesity (IFSO)

6th World Congress of the International Federation for the Surgery of Obesity (IFSO)

5th Congress of the International Federation for the Surgery of Obesity (IFSO)

5th Congress of the International Federation for the Surgery of Obesity (IFSO)

5th Congress of the International Federation for the Surgery of Obesity (IFSO)

5th Congress of the International Federation for the Surgery of Obesity (IFSO)

Hotel Reservation Form<BR></BR> 13th International Symposium on Obesity Surgery<BR></BR> 4th Congress of the International Federation for the Surgery of Obesity (IFSO)<BR></BR> September 22-25, 1999 - SALZBURG

Hotel Reservation Form<BR></BR> 13th International Symposium on Obesity Surgery<BR></BR> 4th Congress of the International Federation for the Surgery of Obesity (IFSO)<BR></BR> September 22-25, 1999 - SALZBURG

Executive and Councils of the International Federation for the Surgery of Obesity (IFSO), 1998-1999

Executive and Councils of the International Federation for the Surgery of Obesity (IFSO), 1998-1999

Congress Registration Form<BR></BR> 13th International Symposium on Obesity Surgery<BR></BR> 4th Congress of the International Federation for the Surgery of Obesity (IFSO)<BR></BR> September 22-25,1999 - SALZBURG

Congress Registration Form<BR></BR> 13th International Symposium on Obesity Surgery<BR></BR> 4th Congress of the International Federation for the Surgery of Obesity (IFSO)<BR></BR> September 22-25,1999 - SALZBURG

International Federation for the Surgery of Obesity (IFSO)<BR></BR> Affiliated Individual Member Application

International Federation for the Surgery of Obesity (IFSO)<BR></BR> Affiliated Individual Member Application

The 13th International Symposium on Obesity Surgery and the 4th Congress of the International Federation for the Surgery of Obesity (IFSO) will be held at the University of Salzburg, Faculty of Natural Sciences, Austria September 23-25, 1999

The 13th International Symposium on Obesity Surgery and the 4th Congress of the International Federation for the Surgery of Obesity (IFSO) will be held at the University of Salzburg, Faculty of Natural Sciences, Austria September 23-25, 1999